Figure 1.
Reduction of CD4+ T cells and HTLV-1 viral load following denileukin diftitox and alemtuzumab. Results are depicted as HTLV-1 copies per microgram of DNA relative to time (♦). The number of CD4+ cells per cubic millimeter was determined by FACS analysis using antihuman CD4 antibody. Results are depicted as CD4+ cells per cubic millimeter relative to time (•). Denileukin diftitox and alemtuzumab treatment periods are indicated as bars above the line graphs.